Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626611 · ClinicalTrials.gov registry record · Phase 2
Multi Immunotherapy to Test Tolerance and Xolair
A Phase 2 study of Food Allergy, sponsored by Kari Christine Nadeau.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT02626611: Completed Phase 2 study of Food Allergy, sponsored by Kari Christine Nadeau.
NCT02626611 is a Phase 2 study of Food Allergy that has completed, run by Kari Christine Nadeau. The registered enrollment target is 70 participants, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626611, a Phase 2 study of Food Allergy, has completed, sponsored by Kari Christine Nadeau.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a phase 2 randomized, double-blind, placebo controlled study which will be conducted at multiple centers in the U.S. All subjects will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in Investigational New Drug (IND) 14831). All subjects will receive Omalizumab for 16 weeks. The subject's allergens will be introduced in a rush desensitization day at week 8. Subjects will return to clinic to escalate the dose of their allergens until 2,000mg protein of each allergen is reached Subjects will return to clinic for a DBPCFC to each allergen at week 30. If subjects are nonreactive to 2 or more allergens during their DBPCFC at week 30 they will be randomized to one of three double blinded arms: Arm A- continue with current dose (2000 mg each food allergen protein), Arm B-300 mg of each food allergen protein, Arm C-placebo (avoiding food allergen protein), their current dose. All subjects will return to clinic for a DBPCFC to each allergen at week 36. The final challenge of week 36 will be the final end of study visit. Safety is a paramount concern in the study design and will be monitored carefully throughout the study. Study subjects and their parents/guardians will receive extensive education on food allergy reactions and medication use.
Primary Outcome
Number of FA participants who pass a DBPCFC to 2,000 mg each of 2 allergens (i.e. no reaction of grade 1 or more according to Bock's criteria) at week 36, will be reported.
Conditions Studied
Interventions
- DRUG Omalizumab
- DRUG Food Flour Buildup
Study Locations (7)
California
- Children's Hospital of Los Angeles - Los Angeles
- Sean N. Parker Center for Allergy Research at Stanford University - Mountain View
Illinois
- Lurie Children's Hospital, Northwestern University - Chicago
New York
- Mt. Sinai, Icahn School of Medicine - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Washington
- Northwest Asthma & Allergy Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-11-16 |
| Phase | Phase 2 |
What the finished NCT02626611 record still lists
NCT02626611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which Omalizumab is the first listed.
NCT02626611 lists 7 locations in 6 states (California, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT02626611 about?
NCT02626611 is a clinical study titled "Multi Immunotherapy to Test Tolerance and Xolair". This is a phase 2 randomized, double-blind, placebo controlled study which will be conducted at multiple centers in the U.S. All subjects will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in Investigational New Drug (IND) 14831). All subjects wil...
What is the current status of trial NCT02626611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2015-12. Estimated completion is 2016-11-16.
What conditions does trial NCT02626611 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT02626611?
The interventions under investigation include: Omalizumab (DRUG), Food Flour Buildup (DRUG).
Who is sponsoring clinical trial NCT02626611?
This trial is sponsored by Kari Christine Nadeau, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02626611 being conducted?
This trial has 7 study locations across California, Illinois, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02626611's enrollment target sits among peer trials
70 10th of 17 higher than 8 of 17 other Food Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Food Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia